This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Articles

Discussion on Pharmacotherapy of Social Anxiety Disorder

Published: May 21, 1998

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Dr. Westenberg: I want to comment on your data and the cognitive effects of SSRIs. We did a study with fluvoxamine in panic disorder where we challenged with CCK4 before and after treatment and found that cognitions about somatic symptoms diminished rather than the physical symptoms themselves.1 The emphasis was on cognitions about people’s situations, about somatic symptoms that disappeared or diminished on treatment, when these panic attacks were elicited by a pharmacologic compound, suggesting that SSRIs do have an effect on negative cognitions, which is also apparent in social phobia.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 59

Quick Links: Journal

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...